ArticleBMC gastroenterology2013
Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.
Article in BMC gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy of Magnetic Sphincter Augmentation versus Nissen Fundoplication for Gastroesophageal Reflux Disease in Short Term: A Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2017Pooled it
- A Cross-Sectional Dual-Site Analysis of the Gastric Antral and Duodenal Mucosa-Associated Microbiome Across Gastroesophageal Reflux Disease Phenotypes.Biomedicines · 2026Article
- Diagnostic accuracy of gastric filling ultrasound combined with BMI for gastroesophageal reflux disease.Frontiers in medicine · 2026Article
- The Economic Cost of Obesity: A Cost-of-Illness Study in Greece.Applied health economics and health policy · 2026Article
- Economic impact of steroid-induced comorbidities in severe asthma: a SHARP CRC simulation.ERJ open research · 2025Article
- Assessment of Burden of Partial Response to Standard Doses of Proton Pump Inhibitors in Patients with Clinically Diagnosed Gastroesophageal Reflux Disease: A Real-World Evidence Study in India.Drugs - real world outcomes · 2025Article
- Sources of information on surgical options for patients undergoing antireflux surgery: a single-center questionnaire-based survey.BMC gastroenterology · 2023Article
- Hiatal hernia repair with transoral incisionless fundoplication versus Nissen fundoplication for gastroesophageal reflux disease: A retrospective study.Endoscopy international open · 2023Article
- Validation of the Short-Form Esophageal Hypervigilance and Anxiety Scale.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Article
- Trends in gastroesophageal reflux disease research: A bibliometric and visualized study.Frontiers in medicine · 2022Article
- Prevalence and risk factors of gastroesophageal reflux disease in a rural Indian population.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole.Journal of neurogastroenterology and motility · 2020Article
- Factors associated with dental erosions in gastroesophageal reflux disease: a cross-sectional study in patients with heartburn.Medicine and pharmacy reports · 2020Article
- Correlates of gastroenterology health-services utilization among patients with gastroesophageal reflux disease: a large database analysis.Israel journal of health policy research · 2019Article
- Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study.BMC gastroenterology · 2013Observational
- Evaluation of a Self-Management Program for Gastroesophageal Reflux Disease in China.Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and AssociatesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD.
methodsPatients with partial response to PPI therapy, defined as persistent GERD symptoms ≥3 days/week despite optimized treatment with a PPI, were recruited for this 12-month observational study. GERD symptoms, HRQL, work productivity and resource use were assessed by patient surveys. Costs were calculated based on lost work productivity and resource use.
resultsThe patient population (n=262; mean age, 54 years; 40% men) carried a significant symptom burden, with 98% of patients having moderate-to-severe GERD symptoms and 65% of patients experiencing daily symptoms at baseline. HRQL and work productivity were significantly impaired, with a greater degree of impairment in patients with higher symptom burden. The mean total cost per patient over the 12-month follow-up period was €5237, of which €4674 (89%) was due to lost work productivity.
conclusionsPartial response to PPI therapy for GERD is associated with a high symptom burden, significant impairment of HRQL and work productivity, and substantial GERD-related costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.